Abstract: A positive electrode active material including a lithium nickel-based composite oxide including secondary particles formed by aggregation of one or more primary particles, wherein a part of cations and a part of anions in the lithium nickel-based composite oxide are substituted, respectively, with cations M? and fluorine anions (F?) in a fluorine-based compound.

Abstract: Provided are an electrode comprising a coated portion that is coated with an active material; an uncoated portion that is not coated with the active material; and at least one selected from the group consisting of a first straight section formed by cutting out a part of the boundary region between the coated portion and the uncoated portion and a second straight section formed by cutting out an edge of the coated portion; an electrode assembly comprising the same; and a manufacturing method of the electrode assembly.

Abstract: The present disclosure relates to a vector pair for screening TDP-43 (TAR DNA-binding protein 43 or TransActive Response DNA-binding protein 43) oligomer formation, a cell line transfected with the vector pair, and a method of monitoring TDP-43 oligomer formation using the cell line. More specifically, the vector pair includes: a first vector including a first TDP-43 gene and a first fluorescence protein gene; and a second vector including a second TDP-43 gene and a second fluorescence protein gene, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first TDP-43 gene and a protein expressed from the second TDP-43 gene. The vector pair is effective in that it makes it possible to monitor TDP-43 oligomer formation in living cells.

Abstract: A battery module includes: a plurality of second battery cells, each including an electrode lead connected to an electrode assembly, a terrace portion of a cell body member in which the electrode assembly is accommodated, and a sealing portion connected to the terrace portion; a housing unit in which the plurality of secondary battery cells are accommodated; and a guard unit including a first area, facing at least a portion of the terrace portion, to delay swelling or bursting of the sealing portion of at least one of the plurality of secondary battery cells. The guard unit has a shape in which a first gap is smaller than a thickness of the cell body member to limit expansion of a thickness of the terrace portion, the first gap being a distance between internal surfaces of the first area.

Abstract: A battery module includes: a plurality of secondary battery cells, each including an electrode lead connected to an electrode assembly, a terrace portion forming a periphery of a cell body member in which the electrode assembly is accommodated, and a sealing portion formed to be connected to the terrace portion; a housing in which the plurality of secondary battery cells are accommodated; and a guard unit installed to face at least a portion of the terrace portion and at least a portion of the sealing portion to delay bursting of the sealing portion of at least one of the secondary battery cells. In the guard unit, a gap between internal surfaces facing the terrace portion is formed to be smaller than a thickness of the cell body member to limit expansion thickness of the terrace portion.

Abstract: The present disclosure relates to a vector pair for screening TDP-43 (TAR DNA-binding protein 43 or TransActive Response DNA-binding protein 43) oligomer formation, a cell line transfected with the vector pair, and a method of monitoring TDP-43 oligomer formation using the cell line. More specifically, the vector pair includes: a first vector including a first TDP-43 gene and a first fluorescence protein gene; and a second vector including a second TDP-43 gene and a second fluorescence protein gene, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first TDP-43 gene and a protein expressed from the second TDP-43 gene. The vector pair is effective in that it makes it possible to monitor TDP-43 oligomer formation in living cells.

Abstract: Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.

Abstract: Disclosed is a levosimendan compound, an optically active isomer thereof, or a pharmaceutically acceptable salt thereof, which is used for the prevention and/or treatment of diseases caused by tau aggregation or phosphorylation, such as neurodegenerative diseases (e.g., Alzheimer disease). In accordance with yet another aspect of the present invention, there is provided a health functional food for preventing or treating tau aggregation-related diseases, containing a levosimendan compound or a pharmaceutically acceptable salt, stereoisomer or solvate thereof.

Abstract: Disclosed is a vector pair for screening tau oligomer formation, a mouse embryo introduced with the vector pair, a transgenic model mouse of neurological disease, obtained from the mouse embryo, and a method of screening a tau oligomer formation inhibitor candidate using the transgenic model mouse. More specifically, the present invention provides vector pair for screening tau oligomer formation, comprising: a first vector comprising a first tau gene, a first fluorescence protein gene and a first neuron-specific promoter; and a second vector comprising a second tau gene, a second fluorescence protein gene and a second neuron-specific promoter, wherein a protein expressed from the first fluorescence protein gene and a protein expressed from the second fluorescence protein gene bind to each other to display fluorescence, by association between a protein expressed from the first tau gene and a protein expressed from the second tau gene.